Novo Nordisk provides update on the ZEUS phas...

Ziltivekimab failed to reduce cardiovascular events in phase 3; impairment charge expected.

What the company is saying

Novo Nordisk reports that ziltivekimab did not reduce major adverse cardiovascular events (MACE) versus placebo in the ZEUS phase 3 trial, citing a hazard ratio of 0.99 (95% CI: 0.88 to 1.11). The announcement emphasizes target engagement and IL-6 pathway inhibition, but concedes these did not translate into clinical benefit. Safety is referenced, with similar overall adverse event rates but a higher rate of serious infections in the treatment arm, though no numerical data is provided. The company asserts the result will not affect its previously communicated adjusted operating profit outlook for 2026, but will trigger a non-cash impairment charge in Q3 2026. Two additional cardiovascular outcomes trials (HERMES and ARTEMIS) are highlighted as ongoing, with readouts expected in the first half of 2027. The tone is neutral, with no attempt to reframe the negative result as a positive or to overstate future prospects. No revenue, cost, or direct financial performance data for ziltivekimab is disclosed.

What the data suggests

The only concrete efficacy data disclosed is the hazard ratio for MACE of 0.99 (95% CI: 0.88 to 1.11), indicating no statistically significant difference between ziltivekimab and placebo. Over 6,300 participants were enrolled, with inclusion criteria of hsCRP levels ≥2 mg/L, and dosing was once-monthly at 15 mg. No numerical data is provided for reductions in IL-6, hsCRP, adverse event rates, serious infections, or all-cause mortality. The financial impact is limited to a non-cash impairment charge in Q3 2026, with no amounts specified. The company states its 2026 adjusted operating profit outlook remains unchanged, but this is unsupported by any financial figures. The announcement lacks period-over-period financial data, revenue, or R&D spend related to the trial or asset. Overall, the data confirms the primary endpoint was not met and provides little basis for assessing financial trajectory or operational impact.

Analysis

The announcement is factual and restrained, reporting that the ZEUS phase 3 trial for ziltivekimab did not achieve a reduction in major adverse cardiovascular events (MACE) versus placebo. The language is neutral, with no promotional or exaggerated claims about efficacy or future prospects. Forward-looking statements are limited to the continuation and anticipated readout dates of two additional trials (HERMES and ARTEMIS) and a non-cash impairment charge in Q3 2026. There is no attempt to inflate the significance of the results, and the company explicitly states that the outcome will not impact its previously communicated profit outlook. No profitability, revenue, or operational growth metrics are disclosed, and the only capital signal is the impairment charge, which is a direct consequence of the trial outcome. The gap between narrative and evidence is minimal, as the announcement does not attempt to reframe the negative result as a positive or overstate future potential.

Risk flags

• ●The failure to demonstrate MACE risk reduction in a large phase 3 trial eliminates near-term commercial potential for ziltivekimab in the studied indication, raising the risk that future trials may also fail to show benefit.
• ●No numerical safety data is disclosed for adverse events or serious infections, limiting independent assessment of the risk profile and potentially obscuring safety signals that could impact future development.
• ●The financial disclosure is minimal, with no quantification of the impairment charge or any offsetting cost savings, making it difficult to assess the true financial impact of the failed trial.
• ●Future value is now contingent on the success of two ongoing trials (HERMES and ARTEMIS), both of which will not report results until the first half of 2027, introducing multi-year execution and clinical risk with no interim milestones disclosed.

Bottom line

This announcement confirms that ziltivekimab failed to reduce major cardiovascular events in a large phase 3 trial, removing any near-term commercial upside for this indication. The company will take a non-cash impairment charge in Q3 2026, but provides no detail on the size or broader financial impact. No efficacy or safety data beyond the headline hazard ratio is disclosed, limiting transparency and making independent risk assessment difficult. The narrative is factual and restrained, with no attempt to spin the negative result, but also offers little new information for investors seeking financial clarity. Any future value from ziltivekimab now depends entirely on ongoing trials in heart failure and post-acute heart attack, with readouts not expected until 2027. Investors should treat this as a clear negative for the cardiovascular pipeline, with the main takeaway being the lack of efficacy in the ZEUS trial and the deferral of any potential upside to at least 2027.

Announcement summary

(LSE/AIM:0QIU) Novo Nordisk announced headline results from the ZEUS cardiovascular outcomes phase 3 trial, stating that ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP), but this did not translate into major adverse cardiovascular events (MACE) risk reduction versus placebo (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11). ZEUS was a double-blind, placebo-controlled trial enrolling over 6,300 people with ASCVD, CKD, and inflammation, as measured by hsCRP levels ≥2 mg/L. The trial evaluated once-monthly ziltivekimab 15 mg versus placebo for reducing the risk of MACE, defined as cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke. Overall rates of adverse events (AEs) and serious AEs in people treated with ziltivekimab were similar to those observed with placebo, but a higher proportion of people treated with ziltivekimab had serious infections compared to placebo. No difference in all-cause mortality was observed. The outcome of ZEUS will not impact Novo Nordisk’s previously communicated adjusted operating profit outlook for 2026 but will result in a non-cash impairment charge in Q3 2026. The two additional ongoing cardiovascular outcomes trials investigating ziltivekimab in people with heart failure (HERMES) and in people following an acute heart attack (ARTEMIS) are planned to continue and are anticipated to read out in the first half of 2027.

Disagree with this article?